List of NGM Biopharmaceuticals patents

Patents where

Current Assignee

Name

NGM Biopharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11548942 Methods of treating a wasting syndrome, increasing growth hormone levels, and increasing GHSR activity with a LEAP2 antibody	Patent 11548942 was granted and assigned to NGM Biopharmaceuticals on January, 2023 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	11548942	January 10, 2023
‌ US Patent 10456449 Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases	Patent 10456449 was granted and assigned to NGM Biopharmaceuticals on October, 2019 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	10456449	October 29, 2019
‌ US Patent 11596676 Methods of treating nonalcoholic steatohepatitis comprising administering an anti-human beta klotho antibody or binding fragment thereof		NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	11596676	March 7, 2023
‌ US Patent 11370841 Methods of treating fibroblast growth factor 19-mediated cancers and tumors		NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	11370841	June 28, 2022
‌ US Patent 11530260 Compositions and methods of use for treating metabolic disorders		NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	11530260	December 20, 2022
‌ US Patent 9920118 Compositions and methods of use for treating metabolic disorders	Patent 9920118 was granted and assigned to NGM Biopharmaceuticals on March, 2018 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	9920118	March 20, 2018
‌ US Patent 10195250 Compositions and methods of use for treating metabolic disorders	Patent 10195250 was granted and assigned to NGM Biopharmaceuticals on February, 2019 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	10195250	February 5, 2019
‌ US Patent 11566067 Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof		NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	11566067	January 31, 2023
‌ US Patent 11358995 Compositions and methods of use for treating metabolic disorders	Patent 11358995 was granted and assigned to NGM Biopharmaceuticals on June, 2022 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	11358995	June 14, 2022
‌ US Patent 11564972 Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subject	Patent 11564972 was granted and assigned to NGM Biopharmaceuticals on January, 2023 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	11564972	January 31, 2023
‌ US Patent 10323075 Compositions and methods of use for treating metabolic disorders	Patent 10323075 was granted and assigned to NGM Biopharmaceuticals on June, 2019 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	10323075	June 18, 2019
‌ US Patent 9550819 Compositions and methods of use for treating metabolic disorders	Patent 9550819 was granted and assigned to NGM Biopharmaceuticals on January, 2017 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	9550819	January 24, 2017
‌ US Patent 10744185 Methods of using variants of FGF19 polypeptides for the treatment of pruritus		NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	10744185	August 18, 2020
‌ US Patent 9161966 GDF15 mutein polypeptides	Patent 9161966 was granted and assigned to NGM Biopharmaceuticals on October, 2015 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	9161966	October 20, 2015
‌ US Patent 11065302 Compositions comprising fusion variants of FGF19 polypeptides	Patent 11065302 was granted and assigned to NGM Biopharmaceuticals on July, 2021 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	11065302	July 20, 2021
‌ US Patent 10413590 Methods of using compositions comprising variants of FGF19 polypeptides for reducing body mass in a subject	Patent 10413590 was granted and assigned to NGM Biopharmaceuticals on September, 2019 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	10413590	September 17, 2019
‌ US Patent 11066454 Compositions comprising variants and fusions of FGF19 polypeptides	Patent 11066454 was granted and assigned to NGM Biopharmaceuticals on July, 2021 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	11066454	July 20, 2021
‌ US Patent 10961315 Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody	Patent 10961315 was granted and assigned to NGM Biopharmaceuticals on March, 2021 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	10961315	March 30, 2021
‌ US Patent 9828415 Compositions and methods of use for treating metabolic disorders	Patent 9828415 was granted and assigned to NGM Biopharmaceuticals on November, 2017 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	9828415	November 28, 2017
‌ US Patent 9834586 Compositions and methods of use for treating metabolic disorders	Patent 9834586 was granted and assigned to NGM Biopharmaceuticals on December, 2017 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	9834586	December 5, 2017
‌ US Patent 9827291 Compositions and methods of use for treating metabolic disorders	Patent 9827291 was granted and assigned to NGM Biopharmaceuticals on November, 2017 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	9827291	November 28, 2017
‌ US Patent 9738716 Beta klotho binding proteins and methods of use thereof	Patent 9738716 was granted and assigned to NGM Biopharmaceuticals on August, 2017 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	9738716	August 22, 2017
‌ US Patent 10398758 Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions	Patent 10398758 was granted and assigned to NGM Biopharmaceuticals on September, 2019 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	10398758	September 3, 2019
‌ US Patent 10434144 Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders	Patent 10434144 was granted and assigned to NGM Biopharmaceuticals on October, 2019 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	10434144	October 8, 2019
‌ US Patent 10562965 Compositions and methods of use for treating metabolic disorders	Patent 10562965 was granted and assigned to NGM Biopharmaceuticals on February, 2020 by the United States Patent and Trademark Office.	NGM Biopharmaceuticals	NGM Biopharmaceuticals	United States Patent and Trademark Office	10562965	February 18, 2020

Results per page:

65 results

0 selected

65 results

0 selected